Overview

Effects of Tamsulosin 0.4mg on Clinical Outcomes in Korean Men With Severe Symptomatic Benign Prostatic Hyperplasia (BPH)

Status:
Unknown status

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy and safety of tamsulosin 0.4mg (Harnal® D. 0.2mg, 2T) with tamsulosin 0.2mg (Harnal® D 0.2mg, 1T) in patients with severe symptomatic benign prostatic hyperplasia as a first line therapy.

Phase:

N/A

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Tamsulosin